ALLYX THERAPEUTICS
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preserve cognition in patients.
ALLYX THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2018-01-01
Address:
New Haven, New York, United States
Country:
United States
Website Url:
http://www.allyxthera.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
7.81 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Current Advisors List
Current Employees Featured
Founder
Investors List
Life Science Angels
Life Science Angels investment in Venture Round - Allyx Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Convertible Note - Allyx Therapeutics
Official Site Inspections
http://www.allyxthera.com
- Host name: 76.105.208.35.bc.googleusercontent.com
- IP address: 35.208.105.76
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Allyx Therapeutics"
AllyxThera
October 30, 2023. Allyx Therapeutics releases top-line Phase 1a data for ALX-001, demonstrating oral administration is safe and well-tolerated at all doses and achieves full brain receptor occupancy.See details»
Allyx Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Allyx Therapeutics is a clinical-stage biotechnology …See details»
Allyx Therapeutics, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap
Learn more at allyxthera.com. Contact Media: Eliza Schleifstein917-763 …See details»
Careers - AllyxThera
Allyx Therapeutics, Inc. 555 Long Wharf Drive Floor 11. New Haven, CT 06511. …See details»
Allyx Therapeutics - BioCT
Email: [email protected] General Information: Founded in 2019, Allyx Therapeutics is a biotechnology company based in New Haven, CT, developing new therapies to protect synapses from destruction in Alzheimer’s disease …See details»
Allyx Therapeutics - Overview, News & Similar companies
Www.allyxthera.com. Revenue <$5 Million. Industry Business Services General Business …See details»
Allyx Therapeutics Announces License For The Treatment of …
Jan 13, 2021 Today, Allyx Therapeutics announced the completion of a license agreement …See details»
Allyx Therapeutics Announces Positive Phase 1b Multiple …
Mar 11, 2024 The multiple ascending dose study (NCT05804383) examined the safety, …See details»
Allyx Therapeutics Announces First Parkinson’s Disease ... - BioSpace
Sep 4, 2024 Learn more at allyxthera.com. About the Duke Clinical Research Institute. The …See details»
Contact - AllyxThera
Allyx Therapeutics, Inc. 555 Long Wharf Drive Floor 11 New Haven, CT 06511. [email protected]See details»
Allyx Therapeutics Announces Expansion into Parkinson’s Disease ...
Mar 5, 2024 Recently Completed Multiple Ascending Dose Study of ALX-001 in Healthy …See details»
Allyx Therapeutics Announces Expansion into Parkinson’s
Mar 5, 2024 Learn more at allyxthera.com. Contact. Media: Eliza Schleifstein 917.763.8106 …See details»
Allyx Therapeutics Announces First Parkinson’s Disease
Sep 4, 2024 Learn more at allyxthera.com. About the Duke Clinical Research Institute. The …See details»
Our Science - AllyxThera
ALX-001 (previously BMS-984923) is a silent allosteric modulator of mGluR5, a first-in-class …See details»
Allyx Therapeutics Announces First Parkinson’s Disease Patient …
Sep 4, 2024 Allyx continues to advance clinical research of its first-in-class oral compound for …See details»
Allyx Therapeutics Announces First Alzheimer’s Disease
Jun 11, 2024 Learn more at allyxthera.com. Contact. Media: Eliza Schleifstein 917.763.8106 …See details»
Our Approach - AllyxThera
Allyx Therapeutics has obtained an exclusive license for use of ALX-001 (BMS-984923) from …See details»
Allyx Therapeutics Announces Positive Phase 1b ... - Markets Insider
Mar 11, 2024 Learn more at allyxthera.com. Contact. Media: Eliza Schleifstein 917.763.8106 …See details»
News and Events - AllyxThera
2024 Michael J. Fox Foundation Parkinson’s Disease Therapetuics Conference – October 17, …See details»